Filters
Save & Share
Clear Filters
Location
Explore options near your center - or near your patient's home.
Diagnosis
MDS Type
Please select the patient's MDS type.
Treatment History
Has this patient ever received treatment for their MDS?
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Trials Near Add Your Location
Accepting patients
MBG453
TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial
Learn more- Monoclonal Antibody
- TIM-3
- Phase 2
Accepting patients
Post-Transplant Cyclophosphamide
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
Learn more- Allogeneic Stem Cell Transplant
- Chemotherapy
- Phase 2
Accepting patients
Mismatched Related vs. Matched Unrelated Donor
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Learn more- Allogeneic Stem Cell Transplant
- Monoclonal Antibody
- Phase 3
Accepting patients
NK Cells Plus Vactosertib
A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer and Relapsed/Refractory Hematologic Malignancies
Learn more- Kinase Inhibitor
- Natural Killer Cells (Allogeneic)
- Phase 1
Not yet accepting
Venetoclax-Enhanced Reduced Intensity Conditioning
A Phase II Trial of Venetoclax-Enhanced Reduced Intensity HLA-Mismatched Allogeneic Transplant for Ultra-High-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Learn more- BCL-2 Inhibitor
- Phase 2
Accepting patients
A Phase I/II Clinical Trial of "Off-the-shelf" NK Cell Administration in Combination With Allogeneic SCT to Decrease Disease Relapse in Patients With High-risk Myeloid Malignancies Undergoing Matched Related, Matched Unrelated, One Antigen Mismatched Unrelated, or Haploidentical Stem-cell Transplantation
Learn more- Allogeneic Stem Cell Transplant
- Natural Killer Cells (Allogeneic)
- White Blood Cell Stimulant
- Phase 1/2
Accepting patients
SL-172154
An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Learn more- Phase 1
Accepting patients
Orca-T
A Single Center, Non-Randomized, Phase 1b Study of Orca-T Following Escalated Dose of Total Marrow and Lymphoid Irradiation in Patients With Acute Leukemias and MDS
Learn more- T Cell (Allogeneic)
- Phase 1
Accepting patients
STIMULUS MDS-US
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Learn more- Hypomethylating Agents (HMA)
- Monoclonal Antibody
- Phase 2
- Has results
Accepting patients
Cladribine, Cytarabine and Venetoclax for HR-MDS
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
Learn more- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 2
- Has results
Filters
Save & Share
Location
Explore options near your center - or near your patient's home.
Diagnosis
MDS Type
Please select the patient's MDS type.
Treatment History
Has this patient ever received treatment for their MDS?
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Advanced Filters
Trial Enrollment Status
Treatment Classifications
Explore trials based on treatment classification/type.
Trial Type
Phase
Bone Marrow Blasts %
Enter this patient's bone marrow blasts %. If results include a range (5-10%), please use the higher number.
Hypomethylating Agent
Has this patient been treated with a hypomethylating agent (HMA) such as azacitidine and/or decitabine?
Stem Cell Transplant
Has this patient received a prior allogeneic (donor) stem cell transplant?
MDS Classification
Has this patient's MDS been classified as primary (cause unknown) or secondary (treatment related)?